This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many months after Amgen’s Amjevita (adalimumab-atto) was released in the
According to data released by LSEG Deals Intelligence, the healthcare sector saw a 35% increase on last year’s deals, reaching $174.6 billion in the first half of 2023 – a
The Centers for Medicare and Medicaid Services (CMS) has made some minor changes to its plan to allow Medicare to negotiate some drug prices after a series of lawsuits fro
The FDA has approved BioMarin Pharma’s Roctavian as the first gene therapy for haemophilia A, giving patients an alternative to regular injections of blood clotting factor
